Setting up a modular vaccine manufacturing facility: What it takes | Part 2

Share this Post:

conveyor belt with small vaccine bottles labeled vaccine in a sterile manufacturing line with automated filling machinery nearby.

Modular vaccine manufacturing facility cost, compliance and execution.

Building a vaccine manufacturing facility is a significant capital project. But the headline construction cost is only one part of the equation.

A vaccine manufacturing plant also needs sophisticated utilities, environmental controls, process equipment, quality-control infrastructure, qualification and validation. It needs to be designed around regulatory expectations and, ideally, around the manufacturer’s future production requirements.

For this reason, asking “What does a modular vaccine manufacturing facility cost?” without defining the project can produce a misleading answer.

The more useful question is, “What factors determine the total cost of establishing a modular vaccine manufacturing facility?”

What determines modular vaccine manufacturing facility cost?

There is no single cost figure that applies to every modular vaccine facility.

The cost can vary substantially depending on the vaccine platform, production capacity, level of containment, cleanroom requirements, process equipment, site conditions and degree of modularisation.

Some of the biggest cost drivers include:

1. Production capacity.

A facility designed for small-scale clinical or pilot production will have very different requirements from a commercial-scale vaccine manufacturing plant. Capacity affects the size of manufacturing spaces, equipment, storage, utilities, laboratories and supporting infrastructure.

2. Vaccine technology.

The manufacturing process has a major influence on the facility. Different vaccine platforms can require different process equipment, environmental controls, containment measures and utility requirements. The facility therefore needs to be designed around the specific product and process rather than around a generic “vaccine facility” template.

3. Cleanroom requirements.

The number and classification of controlled areas can have a significant impact on both construction and operating costs. HVAC, filtration, pressure control, monitoring systems and specialised finishes all contribute to the cost of a controlled manufacturing environment.

4. Process equipment.

Process equipment can represent a substantial part of overall project expenditure. Depending on the process, this may include bioreactors, purification systems, formulation equipment, filling systems, autoclaves, freezers, cold-storage systems and other specialised equipment.

5. Utilities.

Utilities are another major consideration. Water systems, HVAC, clean steam, compressed gases, electrical systems and other process utilities need to be appropriately designed and sized. WHO’s qualification guidance specifically identifies systems such as water purification, HVAC, compressed air, gas and steam systems among the systems that may need qualification.

6. Site conditions.

A modular solution can reduce certain site-based construction activities, but the site still matters. Available infrastructure, power supply, water availability, transportation access, existing buildings and local construction capabilities can all influence the project. The more challenging the site, the more important early engineering and planning become.

Does modular construction make a vaccine facility cheaper?

Not necessarily. And this is an important distinction.

Modular construction should not automatically be sold as a way to make every project cheaper. Instead, its value can come from how it changes the project timeline, execution model, labour requirements, quality control and future flexibility.

Some costs may increase because modules require detailed engineering, factory fabrication, transportation and specialised integration. At the same time, some site activities can be reduced or moved off-site.

A modular approach can also enable parallel workstreams. While site preparation and foundations are underway, modules can be fabricated elsewhere. That can potentially shorten the overall project schedule. And time has an economic value.

Earlier commissioning can mean earlier production. Faster expansion can mean earlier access to additional capacity. Reduced disruption during future modifications can also have operational value.

So when evaluating modular vaccine manufacturing facility cost, it is better to look beyond the initial construction quotation. Instead, consider the total project and lifecycle cost.

The case for a hybrid vaccine manufacturing facility.

There is an option between conventional construction and a fully modular facility: a hybrid model.

The basic principle is straightforward:

Use conventional construction where permanence, structural integration and site-specific requirements make sense. Use prefabricated and modular systems where speed, flexibility and repeatability provide an advantage.

Rather than treating conventional and modular construction as competing approaches, the facility can be broken into different areas and each area can use the approach best suited to its requirements.

For a vaccine manufacturing project, this could mean a permanent core building containing structural infrastructure and major utilities, combined with modular cleanroom or process areas. The exact configuration depends on the manufacturing process and project requirements.

Qualification and validation need to start early.

One of the biggest mistakes in facility development is treating qualification and validation as something that happens after construction.

For a vaccine manufacturing facility, they need to influence the project from the beginning. WHO guidance describes qualification as documented evidence that premises, systems, utilities and equipment have been designed, installed and operated appropriately for their intended purpose.

That means the project needs a clear understanding of:

  • User requirements
  • Design requirements
  • Equipment specifications
  • Utility requirements
  • Factory acceptance testing
  • Installation qualification
  • Operational qualification
  • Performance qualification
  • Cleaning and process validation
  • Environmental monitoring

When modular components are fabricated away from the final site, factory testing can become particularly relevant. Some systems can be inspected and tested before they reach the site, reducing the amount of work that needs to be completed after installation.

But this does not eliminate site qualification. The completed facility still needs to demonstrate that its systems work together as intended in the actual operating environment.

Building flexibility into the facility.

The value of a modular vaccine manufacturing facility becomes even more apparent when future requirements are uncertain.

Imagine a manufacturer establishing a facility for one vaccine today but expecting additional products in the future.

A rigid facility may require significant construction work to accommodate those products. A modular or hybrid facility can instead be designed around future interfaces. That could include provisions for additional process areas, expansion modules, utility connections or additional manufacturing capacity. This is particularly relevant as vaccine manufacturing becomes more diverse and manufacturers increasingly need to support multiple products and technologies.

Flexibility needs to be considered alongside compliance, rather than instead of it.

Choosing the right construction model.

So, should a vaccine manufacturer choose a modular facility? There isn’t a universal answer. The right approach depends on the project.

A fully modular solution may make sense when speed, repeatability and deployment flexibility are major priorities.

A conventional facility may be appropriate where the project has highly specific structural or site requirements.

A hybrid facility may be more appropriate where the project needs to combine permanent infrastructure with flexible, prefabricated manufacturing environments.

This is why the decision should be made after assessing the manufacturing process, site, capacity, timeline, regulatory requirements and future expansion plans.

The goal isn’t to use modular construction because it is fashionable. It is to use it where it solves a genuine project problem.

A practical approach to setting up a modular vaccine manufacturing facility.

A project can broadly be approached through the following stages:

1. Define the manufacturing process. Establish the vaccine platform, production scale, batch sizes and process requirements.

2. Establish regulatory and GMP requirements. Identify the applicable regulatory framework, facility standards, biosafety requirements and quality expectations.

3. Develop the facility concept. Map manufacturing, QC, storage, personnel and material flows.

4. Define utilities and equipment. Establish the requirements for HVAC, water, steam, gases, power and process equipment.

5. Identify what should be modular. Determine which facility areas would benefit from prefabrication and which are better addressed through conventional construction.

6. Design for qualification and validation. Build testing, documentation and validation requirements into the design rather than adding them later.

7. Plan future expansion. Identify potential production changes and establish interfaces that can accommodate future growth.

8. Fabricate, construct and integrate. Where appropriate, modules can be fabricated and tested off-site while site works progress in parallel.

9. Qualify and validate. Verify that premises, utilities, equipment and processes perform as intended.

10. Commission and operate. The final objective is not simply a completed building. It is a qualified manufacturing facility capable of producing vaccines consistently and reliably.

Choosing the right construction model.

A modular vaccine manufacturing facility can offer a different way of approaching one of the most complex types of pharmaceutical infrastructure.

But modularisation isn’t a shortcut around good engineering or GMP.

The facility still needs appropriate cleanrooms, utilities, equipment, environmental controls, quality systems and validation. What modular construction changes is how some of that infrastructure is delivered.

For manufacturers looking at vaccine capacity in new markets, expanding existing production or preparing for future demand, the most useful question may therefore not be whether to choose modular or conventional construction.

It may be, which parts of our vaccine manufacturing facility should be modular, which should be conventionally built, and how can the two work together?

That is where a hybrid or fusion approach can become valuable. By combining permanent infrastructure with prefabricated and modular environments where they make the most sense, manufacturers can design facilities around their actual operational needs rather than forcing the entire project into a single construction model.

And when the requirements of vaccine manufacturing change, the facility can be designed to change with them. That’s the most important advantage of going the hybrid way.

podtech logo
AUTHOR

PodTech

PodTech manufactures prefabricated cleanrooms, plug-and-play PODULE facilities for Life Sciences, Advanced Technology Facilities and Data Centers industries like pharma, Healthcare, Medical Devices & Diagnostics, biotech, Semiconductor and aerospace clients across the GCC and Asia-Pacific. Each unit arrives pre-engineered and pre-validated, with air handling, controls and utilities built in.

Chat with us WhatsApp Chat